Trelegy Ellipta
Payments companies reported to CMS as associated with Trelegy Ellipta. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Trelegy Ellipta, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Trelegy Ellipta
These are the largest totals companies reported as associated with Trelegy Ellipta. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Erica Gregonis | Richmond, KY | Pulmonary Disease | $25,546.54 |
| Cedric Franklin Rutland | Riverside, CA | Critical Care Medicine (Internal Medicine) | $24,483.43 |
| David Mannino | Lexington, KY | Internal Medicine | $24,195.99 |
| Nathanael Brady | Colorado Springs, CO | Allergy | $22,587.64 |
| William Frazier | Canton, MS | Pulmonary Disease | $22,118.44 |
| C Schroeder | Beverly Hills, CA | Pulmonary Disease | $18,362.88 |
| Antonio Anzueto | San Antonio, TX | Pulmonary Disease | $17,211.92 |
| Mitchell Schwartz | Towson, MD | Pulmonary Disease | $16,469.69 |
| Ronald Balkissoon | Denver, CO | Pulmonary Disease | $14,644.26 |
| Joseph Boscia | Spartanburg, SC | Pulmonary Disease | $12,901.37 |
Prescribed Trelegy Ellipta?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.